Finasteride is the most-studied hair loss intervention and one of the most-discussed drugs on Reddit. The data is clearer than the discourse; here is the honest read.
Mechanism
Finasteride is a 5-alpha reductase type II inhibitor. It blocks the conversion of testosterone to dihydrotestosterone (DHT) in peripheral tissues. DHT is the primary driver of:
- Androgenetic alopecia (male-pattern baldness): hair follicle miniaturization.
- Benign prostatic hyperplasia (BPH).
Lowering DHT (~70% with 1 mg/day finasteride) halts or reverses both in many men.
Efficacy evidence
Kaufman 1998 (n=1,553, 2-year RCT) is the canonical trial ( Kaufman et al. 1998, n=1553 ):
- 83% of finasteride users maintained or improved hair count vs 28% placebo.
- Photo-documented improvement in 66% vs 7%.
- Benefit visible by 3-6 months; maximum by 12-24 months.
- Benefit holds with continued use; reverses within 6-12 months after stopping.
Dutasteride (different drug, inhibits type I + II 5AR) is more potent; typically reserved for finasteride non-responders. Larger DHT suppression; potentially larger side effect profile.
Side effects: the honest breakdown
RCT rates (Kaufman 1998 + Propecia Phase III trials combined):
| Phase | Dose | Notes |
|---|---|---|
| Decreased libido | 1.8% vs 1.3% placebo | Attributable rate ~0.5% |
| Erectile dysfunction | 1.3% vs 0.7% | Attributable rate ~0.6% |
| Decreased ejaculate volume | 1.2% vs 0.7% | Attributable rate ~0.5% |
| Gynecomastia | <1% | Usually reversible on stopping |
| Post-finasteride syndrome (persistent) | Rare, not quantified in RCTs | Real case reports; mechanism contested |
Observational and forum-reported rates run 5-15%. Some is real; much is nocebo, selection bias, and confounding with normal sexual function aging. The signal that concerns me most is post-finasteride syndrome: a minority report persistent sexual, cognitive, and mood symptoms after stopping the drug, sometimes for years. RCT evidence for PFS causation is weak; but the case reports are not zero, and the reported magnitude in affected individuals is high.
For reference on similar small-pharmacologic longevity accumulations, CTT-level statin trials ( Cholesterol Treatment Trialists Collaboration 2019, n=186854 ) show measurable cardiovascular signal compounding over a decade of use. The same logic applies here for a lifelong finasteride commitment.
Topical as a middle path
Topical finasteride (0.1-0.25% compounded solution) gets absorbed locally into scalp follicles with much lower systemic plasma levels:
- Hair efficacy roughly comparable to oral at 2-year marks in small trials.
- Systemic DHT suppression ~15-30% vs oral's ~70%.
- Lower reported sexual side effect rates.
- Availability: requires compounding pharmacy or specialty telehealth.
For patients who want the alopecia benefit with less systemic exposure, topical is a reasonable middle path. Evidence base smaller than oral but directionally supportive.
Minoxidil as the companion
Topical minoxidil (5% solution or foam; oral minoxidil 1.25-5 mg/day off-label) works through a different mechanism: vasodilation + K-ATP channel opening. Stacks well with finasteride; combo therapy outperforms either alone.
Oral minoxidil 1.25-2.5 mg/day is having a moment: good efficacy, often tolerated, low-cost. Side effects: ankle edema, hypertrichosis (unwanted body hair), mild tachycardia. Blood pressure monitoring advised for first few weeks.
When to consider finasteride
- You have visible androgenetic alopecia progressing and hair matters to you.
- You understand it's a lifelong commitment; stopping reverses benefit.
- You have informed consent on sexual side effect rates (including the PFS controversy).
- You've tried minoxidil alone if curious about a less-systemic approach.
Alternative for the wait-and-see crowd: low-level laser therapy, PRP injections, ketoconazole shampoo. All have smaller effect sizes than finasteride + minoxidil.
When to avoid
- Men trying to conceive in the near term (small fertility-impact signal).
- Men with history of depression (small depression signal in some trials).
- Men with a strong aversion to any sexual side effect risk, given the RCT rates aren't zero.
- Women of child-bearing potential: teratogenic. Not applicable to hair loss in women typically (different mechanism).
Counter-view
Post-finasteride syndrome advocacy groups argue the RCT data dramatically understates durable side effect risk; their case is largely based on case reports and self-selected surveys. Mainstream dermatology argues the drug is safe and well-tolerated for the vast majority; defensible. The intellectual honesty position: the RCT-attributable side effect rates are low, and the PFS signal is real for a small minority, and both can be true simultaneously.
